Horizon Pharma PLC (HZNP.O)
26 Sep 2016
Mon, Sep 12 2016
* In connection with termination of merger, Raptor will be required to pay to Horizon Pharma a termination fee of $30 million Source text for Eikon: [http://bit.ly/2celZU2] Further company coverage:
* Horizon Pharma Plc announces second-quarter 2016 financial results
Specialty pharmaceutical company Horizon Pharma Plc has hired Bank of America Corp to help it explore selling a significant equity stake to an investor that would bolster its balance sheet, people familiar with the matter said on Monday.
* Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance
* Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc.
* Horizon Pharma announces u.s. Patent and trademark office issuance of additional notice of allowance with claims covering Krystexxa (pegloticase) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
* Horizon Pharma Plc announces settlement of Pennsaid(R) (diclofenac sodium topical solution) 2% w/w patent litigation with Amneal Pharmaceuticals Llc
* On April 22, 2016, co,each of Horizon Pharma Plc and Horizon Pharma, Inc. mutually agreed to settle their respective claims against other
* Confirming its full-year 2016 net sales guidance of $1.025 to $1.050 billion - SEC filing
* Says "not interested in revisiting our previous interest in Depomed" Further company coverage: